Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.
Cancers|April 3, 2021
Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer PatientsJulie Labrosse, Anne Lecourt, Alice Hours, et al.
The American Journal of Pathology|June 29, 2011
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumorsRebeca Sanz-Pamplona, Ramón Aragüés, Keltouma Driouch, et al.
JCO Clinical Cancer Informatics|November 12, 2021
Breast Magnetic Resonance Image Analysis for Surgeons Using Virtual Reality: A Comparative StudyMohamed El Beheiry, Thomas Gaillard, Noémie Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2019
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 TrialAnne-Sophie Hamy, Sandrine Tury, Xiaofei Wang, et al.
Plos One|June 10, 2011
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinomaFabien Reyal, Roman Rouzier, Berenice Depont-Hazelzet, et al.
Plos One|November 17, 2011
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvementDavid Hajage, Yann de Rycke, Marc Bollet, et al.
Plos One|February 28, 2017
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancersHélène Bonsang-Kitzis, Delphine Mouttet-Boizat, Eugénie Guillot, et al.
BMC Cancer|August 7, 2021
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trialAlex De Caluwé, Laurence Buisseret, Philip Poortmans, et al.
Cancers|March 6, 2021
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for ImmunotherapyBeatriz Grandal, Manon Mangiardi-Veltin, Enora Laas, et al.
Pageof 20